Bio-Images Research Ltd. Partners Oxthera in "Elimox", the £1.9 Million Project in Primary Hyperoxaluria Drug Development

Published: Sep 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

September 24, 2013 -- Glasgow-based clinical research experts “Bio-Images Research” are today announced as partners in a new EU drug development project: ELIMOX, focusing on development of a pharmaceutical treatment for the genetic condition Primary Hyperoxaluria (PH). The ambitious project which is funded by a £1.9 million FP7 grant (2.1 million€) and co-ordinated by Stockholm-based Swedish biopharmaceutical firm OxThera will incorporate 10 additional partners from across Europe and North America over a 2 year period with the aim of developing a unique bacterial pharmaceutical product for treatment of PH.

The ELIMOX project will perform bacterial drug development, analytical methods development and clinical development for PH. The bacteria, Oxalobacter formigenes, has been shown to actively promote enteric elimination of oxalate in animal models (Hatch, 2011 and 2013) and early exploratory clinical studies evaluating an initial formulation of the bacteria showed a substantial decrease in urinary oxalate excretion in subjects with PH (Hoppe, 2006).

“The research findings from this project will add profound knowledge relating to the impact of probiotic pharmaceutical treatments,” said Elisabeth Lindner, CEO of OxThera and co-ordinator of the ELIMOX project. Speaking on the role which Bio-Images will play in the project i.e. utilising scintigraphic imaging technology to visualise formulation behaviour in vivo, COO of Bio Images Research, Dr Lee Ann Hodges told us: “We are delighted to be part of this project, enabling scintigraphy to be used to its fullest potential in ensuring that the Oxalobacter formulations target the appropriate gastrointestinal regions.”


The ELIMOX project is funded as part of the program “Research for the benefit of specific groups, Research for SMEs”. The consortium includes 12 partners; OxThera AB, Sweden, Cobra Biologics Ltd, UK, SymbioPharm GmbH, Germany, Ergomed Clinical Research Ltd, UK, Universitätsklinikum Bonn, Germany, Hospices Civils de Lyon, France, University College London Hospitals NHS Foundation Trust, UK, Galenica AB, Sweden, K.A.B.S. Laboratories Inc., Canada, Medizinisches Versorgumszentrum Institute für Microökolgie, Germany, TNO, Netherlands and Bio-Images Research Ltd, UK.

About Bio-Images Research

As world leaders in scintigraphic imaging of drug delivery systems, Bio-Images offer a unique clinical research service to the global pharmaceutical and healthcare industry. Gamma scintigraphy allows non-invasive, quantitative assessment of the behaviour of oral, nasal, pulmonary and ophthalmic formulations in man. The data produced allows informed decision making at the crucial early stages of the development pipeline, cutting costs and reducing the time to market.

About Primary Hyperoxaluria

Primary Hyperoxaluria is an uncommon inherited autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. There is a high unmet medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

For further information, please contact

Christopher Murphy

+44 758 111 9094

Help employers find you! Check out all the jobs and post your resume.

Back to news